NCT00106626View on ClinicalTrials.gov

Suberoylanilide Hydroxamic Acid in Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

August 31, 2005

Primary Completion Date

December 31, 2007

Study Completion Date

December 31, 2007

Conditions
Advanced Cancer
Interventions
DRUG

vorinostat (Suberoylanilide Hydroxamic Acid [SAHA]) in combination with Pemetrexed and Cisplatin

Dose escalation study starting with vorinostat (Suberoylanilide Hydroxamic Acid \[SAHA\]) capsules 200 mg b.i.d. in combination with Pemetrexed and Cisplatin (see table for Reporting Groups).

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00106626 - Suberoylanilide Hydroxamic Acid in Advanced Solid Tumors | Biotech Hunter | Biotech Hunter